Biomarker for Inflammatory Bowel Disease
The diagnosis of IBD using CEACAM6 as a biomarker to correlate to loss of PTPN2 activity.
None
Background Inflammatory Bowel Disease (IBD) includes Crohn’s Disease and ulcerative colitis (UC). There is no definitive test for diagnosing IBD and its diagnosis involves a number of invasive tests such as colonoscopies, biopsies and blood tests. Tests that screen for fecal inflammatory biomarkers and serological markers are in development. Given that IBD is a heterogeneous disease and subsets of patients may be defined by genetic and subclinical markers that reflect specific types of inflammation, each IBD subtype represents an opportunity for individualized treatment approaches. Therefore additional biomarkers that may be added to the panel of biomarkers to improve the diagnosis of IBD are essential. Tech ID/UC Case 29390/2018-548-0 Related Cases 2018-548-0
美国
